Literature DB >> 20205680

Osteopontin: an effector and an effect of tumor metastasis.

L A Shevde1, S Das, D W Clark, R S Samant.   

Abstract

Osteopontin (OPN) is a matricellular protein that is produced by multiple tissues in our body and is most abundant in bone. It is also produced by cancer cells and plays a determinative role in the growth, progression and metastasis of cancer. Clinically, OPN has been reported to be upregulated in tumor cells per se; this is also reflected by increased levels of OPN in the circulation. Thus, increased OPN levels the plasma are an effect of tumor growth and progression. Functionally, high OPN levels are determinative of higher incidence of bone metastases in mouse models and are clinically correlated with metastatic bone disease and bone resorption in advanced breast cancer patients. Several research efforts have been made to therapeutically target and inhibit the activities of OPN. In this article we have reviewed OPN in its role as an effector of critical steps in tumor progression and metastasis, with a particular emphasis on its role in facilitating bone metastasis of breast cancer. We have also addressed the role of the host-derived OPN in influencing the malignant behavior of the tumor cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205680      PMCID: PMC6869338          DOI: 10.2174/156652410791065381

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  193 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 2.  Osteopontin.

Authors:  J Sodek; B Ganss; M D McKee
Journal:  Crit Rev Oral Biol Med       Date:  2000

3.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

4.  The carboxyl-terminal fragment of osteopontin suppresses arginine-glycine-asparatic acid-dependent cell adhesion.

Authors:  K Takahashi; F Takahashi; K K Tanabe; H Takahashi; Y Fukuchi
Journal:  Biochem Mol Biol Int       Date:  1998-12

5.  Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways.

Authors:  Subha Philip; Gopal C Kundu
Journal:  J Biol Chem       Date:  2002-12-07       Impact factor: 5.157

6.  Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Stefan A Loening; Klaus Jung
Journal:  Prostate       Date:  2007-02-15       Impact factor: 4.104

7.  Caprine uterine and placental osteopontin expression is distinct among epitheliochorial implanting species.

Authors:  M M Joyce; J F González; S Lewis; S Woldesenbet; R C Burghardt; G R Newton; G A Johnson
Journal:  Placenta       Date:  2005 Feb-Mar       Impact factor: 3.481

8.  A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5.

Authors:  D D Hu; E C Lin; N L Kovach; J R Hoyer; J W Smith
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

9.  Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells.

Authors:  Zhiyong Mi; Tim Oliver; Hongtao Guo; Chengjiang Gao; Paul C Kuo
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

10.  Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells.

Authors:  Gang Song; Yanlin Ming; Yubin Mao; Shideng Bao; Gaoliang Ouyang
Journal:  Exp Biol Med (Maywood)       Date:  2008-10-10
View more
  63 in total

1.  Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions.

Authors:  Christina Reufsteck; Rinat Lifshitz-Shovali; Michael Zepp; Tobias Bäuerle; Dieter Kübler; Gershon Golomb; Martin R Berger
Journal:  Clin Exp Metastasis       Date:  2012-03-11       Impact factor: 5.150

2.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

Authors:  A Mitra; M E Menezes; L K Pannell; M S Mulekar; R E Honkanen; L A Shevde; R S Samant
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

3.  Induction of the MCP chemokine cluster cascade in the periphery by cancer cell-derived Ccl3.

Authors:  Elena Farmaki; Vimala Kaza; Athanasios G Papavassiliou; Ioulia Chatzistamou; Hippokratis Kiaris
Journal:  Cancer Lett       Date:  2016-12-29       Impact factor: 8.679

4.  Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Authors:  J C Hahne; S R Meyer; P Kranke; J Dietl; M Guckenberger; B Polat; A Hönig
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621

5.  Osteopontin is a tumor autoantigen in prostate cancer patients.

Authors:  Tatiana M Tilli; Eloísio A Silva; Lívia C Matos; Douglas V Faget; Bianca F P Dias; Juliana S P Vasconcelos; Yasuyuki Yokosaki; Etel R P Gimba
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

Review 6.  Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.

Authors:  Mahmoud Khattab; Magdy Fouad; Elham Ahmed
Journal:  World J Hepatol       Date:  2015-10-18

7.  Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.

Authors:  Jianfeng Huang; Angeles Duran; Miguel Reina-Campos; Tania Valencia; Elias A Castilla; Timo D Müller; Matthias H Tschöp; Jorge Moscat; Maria T Diaz-Meco
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

8.  Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.

Authors:  Said M Elshafae; Wessel P Dirksen; Aylin Alasonyalilar-Demirer; Justin Breitbach; Shiyu Yuan; Noriko Kantake; Wachiraphan Supsavhad; Bardes B Hassan; Zayed Attia; Lucas B Alstadt; Thomas J Rosol
Journal:  Prostate       Date:  2020-04-29       Impact factor: 4.104

Review 9.  The impact of hypoxia in hepatocellular carcinoma metastasis.

Authors:  Carmen Chak-Lui Wong; Alan Ka-Lun Kai; Irene Oi-Lin Ng
Journal:  Front Med       Date:  2013-11-14       Impact factor: 4.592

10.  Osteopontin Expression in Patients with Hepatolith.

Authors:  Bum Soo Kim; Sun Hyung Joo; Sung Jig Lim; Kwang Ro Joo
Journal:  Indian J Surg       Date:  2013-05-18       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.